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Abstract 
Factors That Affect Treatment Compliance among Individuals with Mental Illness 
By 
 
Marsha D. Brown 
 
Advisor: Professor Elizabeth L. Jeglic 
 
 
Approximately 6% of the American population suffers from a severe mental illness such 
as Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Post-Traumatic Stress 
Disorder, and Obsessive-Compulsive Disorder.  Treatment compliance in individuals 
with severe mental illness is imperative as without treatment these individuals may 
experience homelessness, unemployment, and a decreased life expectancy of up to 34 
years.  Consequently, researchers have increasingly examined factors that may affect 
overall compliance among these individuals, such as insight, social support, symptom 
severity, and substance abuse.  However, many of these studies focus on compliance 
with prescribed medications and few examine compliance with recommended 
psychological treatment.  The current study examined the effects of the aforementioned 
factors on treatment compliance among individuals with severe mental illness and 
substance use diagnoses.  Defendants in an alternative-to-jail program were asked to 
complete a brief clinical interview and several self-report measures examining insight, 
perceived social support, psychiatric symptom severity, and substance use.  Each 
individual’s record was then examined at 3- and 6-month follow-up periods to determine 
the number of re-arrests, re-hospitalizations, and program removals they had 
experienced.  Alcohol addiction severity and social support at intake were found to be 
significant predictors of treatment adherence at six-month follow-up.   These findings 
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will be discussed as they pertain to the implications for identifying and understanding 
the nature of the relationship between the client-centered factors that most directly 
impact treatment compliance among individuals with severe and persistent mental 
illness.   
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Chapter 1: Introduction 
Factors That Affect Treatment Compliance in Individuals with Mental Illness 
Severe Mental Illness in the United States 
The National Alliance on Mental Illness (NAMI) estimates that approximately 57.7 
million adults in the United States (U.S.) suffer from a severe mental illness 
(www.nami.org).  Of the total U.S. adult population, it is estimated that approximately 
1% have Schizophrenia, 2.6% have Bipolar Disorder, 7% have Major Depressive 
Disorder, and 18% have anxiety-related disorders such as Post-Traumatic Stress 
disorder (PTSD) and Obsessive-Compulsive Disorder (OCD).  Although disorders such 
as PTSD and OCD can be severe and persistent in nature, Schizophrenia, Bipolar 
Disorder, and Major Depressive Disorder are generally classified as severe and 
persistent mental illnesses (SPMI) and are more extensively covered in the literature.  
Additionally, research examining SPMI typically examines the above disorders; 
therefore, they will be the focus of this study.   
When compared to a non-mentally ill population, individuals with SPMI have an 
increased likelihood of having a chronic medical condition (Adler, 1991; Carney, et al., 
2006; Colton & Manderscheid, 2006; Sokal, et al., 2004), being unemployed (Cook, 
2006; Goldberg, et al., 2008; Mueser, 2001), utilizing homeless services and/or being 
homeless (nami.org; Fischer & Breakey, 1991; Martens, 2001), and a decreased life 
expectancy of up to 34 years (Colton & Manderscheid, 2006; Dembling, 2001; Dickey, 
et al., 2004).  For individuals with SPMI, getting treatment is very important (Substance 
Abuse and Mental Health Services Administration; NAMI) and treatment adherence is 
imperative to maintain stability in their lives, as non-adherence can result in 
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decompensation, frequent hospitalizations, disruptions in their lives, and the lives of 
their family and friends (Casper & Regan, 1994; O’Toole, et al., 2005; Steinhart, et al., 
1999), and increased contact with the criminal justice system (Glaze & James, 2006; 
Lurigio, 2011; Steadman, Osher, Robbins, Case, & Samuels, 2009 ), especially if the 
individual is homeless (Roy, Crocker, Nicholls, Latimer, & Ayllon, 2014).  Consequently 
there has been a growing body of research examining treatment compliance among 
individuals with mental illness.   
According to Adam and Howe (1993), treatment compliance is defined as how 
closely and fully a patient’s behavior follows medical or health advice.  In many of the 
studies focusing on treatment compliance, researchers have investigated the degree to 
which participants adhere to prescribed psychiatric medications and they relate that 
adherence to factors such as insight, symptom severity, and social support.  It is worth 
noting that many of these studies use the terms compliance and adherence 
interchangeably; however, both terms refer to the act of following medical or health 
advice.     
In an effort to ultimately increase adherence, researchers have examined both 
the static (i.e., fixed) and dynamic (i.e., variable) factors that most strongly affect overall 
compliance in individuals with mental illness. Studies have explored numerous static 
variables such as gender (Atwood & Beck, 1985; Buchanan, 1992), ethnic minority 
status (Tunnicliffe, Harrison, & Standen, 1992), age of illness onset (Leclerc, et al., 
2013),type of psychotic symptoms (Duncan & Rogers, 1998), and level of formal 
education (Barkof, et al., 2011; Leclerc, et al., 2013).  While some of these variables 
can affect compliance, they cannot be changed with intervention.  Several 
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comprehensive research reviews have found that a number of dynamic factors, 
including insight, psychopathology, medication side effects, therapeutic alliance, social 
support, and substance use  can also impact treatment adherence (Barkof, et al., 2011; 
Leclerc, et al., 2013).  However, of all the factors  examined in the current study (insight, 
addiction severity, psychiatric symptom severity, and social support) are patient-focused 
factors which are amenable to change and which appear to be the most important 
determinants of whether an individual will adhere to mental health professionals’ advice 
regarding treatment regimens (Buckley, et al., 2007; Coldham, et al., 2002; Dawson & 
Mullen, 2008; Dixon, McNary, & Lehman, 1995; Duffy, 2008; Duncan & Rogers, 1998; 
Emsley, et al., 2008; Hunt, Bergen, & Bashir, 2002; Pinikahana, et al., 2002; Sipos, et 
al., 2001).  These factors are dynamic in nature and thus can potentially be targeted in 
treatment.    
Patient Insight 
Level of patient insight is a crucial determinant of whether a patient will comply 
with the advice of mental health professionals (Buckley, et al., 2007; Coldham, et al., 
2002; Dawson & Mullen, 2008; Emsley, et al., 2008; Pinikahana, et al., 2002; Sipos, et 
al., 2001) .  There are many aspects of insight including the extent to which an 
individual recognizes that he or she has a mental illness which interferes with cognitive 
functioning, one’s ability to identify certain symptoms/experiences as manifestations of 
mental illness, and one’s ability to recognize the need for medication to manage such 
symptoms.  Research suggests that possession of insight occurs on a continuum and 
fluctuates over the course of one’s illness (Arango & Amador, 2011; Koren, Viksman, 
Giuliano, & Seidman, 2013; Quee, et al., 2011).  The current research on patients with 
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SPMI suggests that patients who lack or have lower levels of insight, specifically those 
who do not recognize they have a SPMI that is in need of treatment, are less likely to 
comply with recommended treatment (Dawson & Mullen, 2008; Emsley, Chilza, & 
Schoeman, 2008; Jonsdottir, et al., 2013; Pinikahana, et al., 2002; Segarra, et al., 2012) 
and may experience greater symptom severity (Segarra, et al., 2010; Sipos, et al., 
2001).  Olfson, Marcus, Wilk, and West (2006) surveyed psychiatrists who treat patients 
with schizophrenia and concluded that, according to the treating psychiatrists, the 
majority of patients who were non-compliant with prescribed medications refused to 
take their medications as a result of low levels of insight.  Although the authors 
considered other variables such as social support and substance abuse, the 
examination of these variables was limited as social support was defined only as family 
involvement and substance abuse was only of interest if it was the primary or sole 
reason for non-adherence to treatment.  Sevy, Nathanson, Visweswaraiah, and Amador 
(2004) also examined patients with schizophrenia and found a relationship between lack 
of insight and symptom severity, such that patients with lower levels of insight 
experienced more severe symptoms.   
While the relationship between schizophrenia and low levels of insight into one’s 
mental illness has been extensively documented (Buckley, et al., 2007; Coldham, et al., 
2002; Dawson & Mullen, 2008; Emsley, et al., 2008; Pinikahana, et al., 2002; Sipos, et 
al., 2001), research has also branched out to study insight in patients with other types of 
severe mental illnesses such as bipolar disorder, schizoaffective disorder, and unipolar 
depression.  For example, Segarra and colleagues (2010) examined the predictive 
value of insight on medication adherence and clinical symptoms among patients with 
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schizophrenia and schizoaffective disorder and found that a higher level of insight at 
baseline predicted a patient’s clinical and functional status at the one-year follow-up, as 
well as their treatment adherence throughout the study for patients with both of the 
aforementioned disorders.  Pini, Cassano, Dell’Osso, and Amador (2001) compared 
insight levels of patients with schizophrenia to those with schizoaffective disorder, 
bipolar disorder, and unipolar depression.  The authors found that levels of insight 
among the patients with schizophrenia did not significantly differ from patients in the 
other groups.  However, in another study Dell’Osso and colleagues (2002) examined 
insight levels in patients with full and mixed mania, bipolar depression, and unipolar 
depression and found that overall, none of the groups had high levels of insight, but 
patients with unipolar depression possessed the highest levels of insight while those 
with mania had the lowest levels of insight.  The authors speculated that since poor 
insight predicts poor treatment adherence among patients with schizophrenia, so too 
may be the case among patients with unipolar and bipolar depression.     
 While level of patient insight may lead directly to medication compliance, other 
variables have been postulated to affect insight and thereby indirectly affect adherence 
to prescribed psychotropic medications.  In 2001, Kamali, et al. studied treatment 
adherence, substance use, and symptom severity among patients with schizophrenia 
and found that patients who were regularly compliant with prescribed medications had 
significantly higher scores on insight measures than patients who were irregularly 
compliant.   In this study, symptom severity was not a significant predictor of adherence, 
however, the authors did find that those participants with a greater number of positive 
symptoms were significantly less likely to be treatment adherent.  When participants 
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with comorbid substance use were removed from the data analysis, a strong significant 
relationship between insight and adherence was found.  However, when participants 
with substance abuse were included, the relationship between insight and adherence 
was much less clear.  This suggests the existence of a complex relationship between 
insight, substance abuse, and treatment adherence.  The exact nature and strength of 
this relationship remains unclear and, therefore, further exploration is imperative.  
Social Support 
Another important determinant of treatment adherence among those with SPMI is 
social support.  Social support refers to interpersonal relationships between a patient 
and family members, friends, counselors, therapists, doctors, and other treatment 
providers.  Procidano and Heller defined social support as, “the extent to which an 
individual believes that his/her need for support, information, and feedback are fulfilled” 
(1983, pg. 2).  Numerous studies have linked poor social support among individuals with 
mental illness to medication non-adherence (Battaglioli-Denero, 2007; Kampman, et al., 
2002; Rabinovitch, et al., 2009; Seo & Min, 2006) and an increased likelihood of being 
court-mandated to treatment (Swartz, Swanson, Kim, & Petrila, 2006).   
Interestingly, social support may not only be a determinant in treatment 
adherence, but it may also have an impact on treatment trajectory.  Joesch and 
colleagues (2013) examined the impact of an evidence-based treatment model for 
depression and anxiety.  The authors concluded that social support was actually a 
protective factor, as they found that participants with higher levels of social support were 
likelier to experience significant recovery from symptoms of depression and anxiety and 
those with lower levels of social support took a greater amount of time to recover and 
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experienced lower levels of symptom relief.   These results highlight the impact of social 
support in not only improving individuals’ treatment adherence, but improving their level 
of symptom relief and decreasing the time it takes clients to return to baseline 
functioning.   
Other studies have looked at the role of social support in predicting treatment 
outcomes unrelated to medication adherence among individuals with primary substance 
use concerns and some symptoms of mental illness. Dodge and Potocky (2000) 
sampled women enrolled in a residential substance abuse treatment program for 12 
months and examined the relationships between social support, addiction severity, and 
depressive symptoms.  The authors determined that social support predicted level of 
depression such that those individuals with lower social support experienced 
significantly higher levels of depressive symptoms.  The authors concluded that social 
support was a stronger predictor and played a significant role in treatment outcome.  
Similarly,Comfort, Sockloff, Loverro, and Kaltenbach (2003) sampled women enrolled in 
residential or outpatient substance abuse treatment for a minimum of three months.  
The authors examined the relationships between treatment outcomes and a number of 
predictor variables including social support and depressive symptoms.  Participants 
were assessed at four separate periods: Intake, six months after program enrollment, 
10 months after program discharge, and 12 months after program discharge.   The 
authors determined that, for participants enrolled in outpatient treatment, overall level of 
social support at intake predicted abstinence from substance use, level of treatment 
engagement, and retention in treatment at six months.  During the 10- and 12-month 
post-discharge periods, social support remained a significant predictor of abstinence, 
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however, the source from which the support was received was a key factor (i.e., from 
non-substance-using family, friends, and acquaintances).  Increased support for daily 
needs was also a significant predictor of continued abstinence at 10 and 12 months for 
outpatient participants.  Interestingly, the authors found very different results for 
participants enrolled in residential treatment.  For this group, level of social support and 
depressive symptoms at intake were not found to be related to treatment outcomes at 
six months. However, level of support with parenting duties was a significant predictor 
during the post-discharge assessment periods.  Authors concluded that social support 
does indeed play an important role in treatment outcome, but hypothesized that perhaps 
the nature of its role and importance changes, depending on treatment setting.     
The preceding studies seem to suggest that, while social support does appear to 
play an important role in overall treatment adherence, the exact nature of its role, impact 
on types of treatment, and relationship with variables such as psychiatric symptom 
severity necessitates further investigation. 
Psychiatric Symptom Severity 
Research has established a relationship between psychiatric symptom severity 
and treatment adherence (Duncan & Rogers, 1998; Macpherson & Jerrom, 1997; Tsang 
et al., 2010), such that as the severity of mental illness symptoms increases, treatment 
adherence decreases (Donohoe, et al., 2001; Kampman & Lehtinen, 1999; Kampman, 
et al., 2002; Tsang et al., 2010).  Among patients with Schizophrenia, those with more 
severe positive and negative symptoms may be less likely to comply with recommended 
treatment (Macpherson & Jerrom, 1997).   
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Among patients with a SPMI other than Schizophrenia, more severe symptoms 
may be related to better compliance.  For example, Sirey and colleagues (2001) 
sampled depressed patients and found that those who rated their symptoms as more 
severe were more likely to be compliant with treatment.  Similarly, Demyttenaere, and 
colleagues (2008) found that, within their sample of depressed patients, those with more 
severe symptoms were more likely to take their medications regularly and complete 
treatment and concluded that, for clients with depression, increased psychiatric 
symptom severity is related to a higher likelihood of treatment compliance.     
One study, which examined medication compliance among patients with SPMI 
other than schizophrenia, failed to find a significant relationship between symptom 
severity and medication compliance (Duffy, 2008).  Duffy (2008) found that more severe 
symptoms did not correlate with decreased medication compliance.  The author noted 
that a majority of the sample were compliant with medications, which may have affected 
the existence of a relationship between psychiatric symptom severity and treatment 
adherence, because patients’ medication adherence may have lessened the presence 
of symptoms, thus making it difficult to ascertain the exact nature of the relationship 
between these two variables.   
However there is some evidence that the relationship between symptom severity 
and adherence is not linear.  For example, Macpherson and Jerrom (1997) assessed 
patients’ psychiatric symptom severity and insight and determined that those patients 
with more severe symptoms and lower levels of insight were less likely to comply with 
treatment, suggesting that the relationship between symptom severity and treatment 
adherence may be moderated by insight.  Overall, research suggests that psychiatric 
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symptom severity does play a vital role in treatment compliance.  However, further 
investigation is needed to determine the ways in which this particular variable interacts 
with other dynamic variables to determine whether an individual with SPMI will comply 
with recommended treatment.    
Substance Use 
Current research estimates show that between 50% and 90% of individuals with 
mental illnesses in general have co-occurring substance use issues (Albanese & Pies, 
2004; Altindag, Yanik, & Nebioglu, 2006; Clark, 2001; Drake, et al., 2001; Leahy, 2007; 
McDonell, et al., 2013; McKowen, Frye, & Gitlin, 2005; Pinikahana, et al., 2002), which 
have been linked to treatment non-adherence (Battaglioli-Denero, 2007; Casper & 
Regan, 1993; Heyscue, Levin, & Merrick, 1998; Jonsdottir, et al., 2013; Smith, 
Barzman, & Pristach, 1997).   Further, individuals with mental illness were found to 
abuse substances at significantly higher rates than the general population (Lev-Ran, 
Imtiaz, Rehm, & Le Foll, 2013).  Swendsen, et al., 2010)    
Comorbid substance use among those with mental illness has been found to be 
strongly positively correlated with negative outcomes including treatment non-
adherence (Battaglioli-Denero, 2007; Casper & Regan, 1993; Heyscue, Levin, & 
Merrick, 1998; Sender-Galloway & Simeon, 2013; Smith, Barzman, & Pristach, 1997).  
Patients with comorbid mental illness and substance use disorder have lower rates of 
treatment completion and lower treatment satisfaction scores than patients with mental 
illness only (Primm, et al., 2000).  Additionally, when compared to individuals with only 
SPMI, individuals with both a severe mental illness and a co-occurring substance use 
disorder may experience worse psychosocial adjustment, a higher rate of 
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hospitalization, more psychotic relapses, and worse short-term outcomes (Drake, 
Mueser, Clark, & Wallach, 1996).  Furthermore, co-occurring substance use has been 
linked to other negative outcomes such as increased likelihood of violent behavior, 
mental illness relapse, lack of housing, a greater likelihood of substance use relapse, 
and greater utilization of substance abuse services (Dixon, McNeary, & Lehman, 1998; 
Drake, et al., 2001; Sender-Galloway & Simeon, 2013).  The negative outcomes of 
patients with a dual diagnosis have implications for the use of mental health and 
substance abuse resources.  Strakowski and colleagues (1998) followed newly 
diagnosed patients with either Bipolar Disorder or Major Depressive Disorder with 
psychotic features for a period of one year.  They found that patients who abused 
substances had poorer treatment adherence and experienced a longer wait for 
symptom relief once they did comply with treatment.  In another study, Clark, 
Samnaliev, and McGovern (2007) investigated the use of mental health resources in 
five state Medicaid programs and found that individuals with both a severe mental 
illness and a substance abuse disorder used the Emergency Department, inpatient 
psychiatric facilities, and outpatient psychiatric facilities at a significantly higher rate than 
did individuals with mental illness alone. More recently, Sender-Galloway and Clark 
(2013) studied forensic patients discharged from a psychiatric hospital and found that 
those individuals with comorbid substance use were significantly more likely to be non-
compliant with medications, miss scheduled appointments, and engage in aggressive 
and/or disruptive behavior as compared to individuals with SPMI and no co-occurring 
substance use disorder.  Participants in this study were also more likely to have 
difficulty managing their activities of daily living (e.g., showering and eating) if they had 
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comorbid substance use issues.    The Sender-Galloway and Clark study further 
illustrates the complexity added by co-morbid substance use when attempting to 
understand treatment compliance among a dual diagnosis population. 
The research to date suggests that co-morbid substance use negatively affects 
treatment outcome among patients with mental illness throughout the course of their 
illness and a large proportion of poor treatment adherence among these patients can be 
attributed to substance use.  Therefore, it is imperative to consider the role of 
substances when investigating factors that affect treatment adherence.  What research 
in this area to date has failed to determine is the amount of its effects and exactly how it 
affects factors such as insight, symptom severity, social support, and overall treatment 
adherence.   
Many studies focusing on factors affecting treatment adherence in patients with 
mental illness fail to consider the effects of substance abuse.  Those studies that do 
consider the impact of substances have yielded interesting and alarming results.  For 
example, some have found that patients with mental illness and substance abuse have 
less social support than those with mental illness alone (Dixon, McNary, & Lehman, 
1995; Van Dorn, et al., 2006).  Kamali and colleagues (2001) studied insight in patients 
with Schizophrenia and found that when they included patients with comorbid substance 
abuse in their analysis, they could not detect any clear and explainable relationship 
between insight and adherence.  These findings further suggest that when examining 
factors affecting treatment adherence, substance abuse should be considered, as it 
appears to share a complex relationship with the other variables of interest.  
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Statement of the Problem 
Most of the current research in the area of treatment compliance examines 
compliance as it pertains to a patient’s decision to take doctor-prescribed medications.  
However, for patients with SPMI, mental health professionals often also recommend 
attending group or individual therapy and substance abuse treatment as an integral part 
of treatment, depending on the patient’s needs (Randall & Finkelstein, 2007).  Research 
shows strong support for the efficacy of treatments such as Cognitive Behavioral 
Therapy (CBT) and social skills training to manage and reduce psychotic and other 
symptoms, as well as to improve patients’ overall functioning (Lecomte, et al., 2008; 
Patelis-Siotia, 2001; Randall & Finkelstein, 2007).  Some studies have even suggested 
that cognitive behavioral-based and similar interventions (such as treatment adherence 
therapy and motivational interviewing), in addition to psychopharmacological 
interventions, may actually enhance a patient’s insight and/or willingness to continue 
taking prescribed medications (Cavezza, Aurora, & Ogloff, 2013; Cochran, 1984; 
Rathod, Kingdon, Smith, & Trukington, 2005; Staring et al., 2010).  Additionally, for 
many patients with illnesses such as bipolar disorder and schizophrenia, medication 
alone does not suffice to decrease symptoms and functional impairment and prevent 
relapse (Patelis-Siotia, 2001).   
Consequently, compliance as it relates to prescribed medications, has been 
widely examined throughout the literature (Hunt, Bergen, & Bashir, 2002; Janssen, et 
al., 2006; Kamali, et al., 2001; Rosenberg, Bleiberg, Koscis, and Gross 2003; Ziguras, 
Klimidis, Lambert, & Jackson, 2001).  Research in this area shows support for the 
powerful influences of factors such as patient insight into illness, addiction severity, 
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psychiatric symptom severity, and social support, on a patient’s compliance with 
prescribed medications.  Although the aforementioned variables have been extensively 
examined in isolation, and in some cases in pairs or triplicate, no one study has 
examined the effects of all four variables.  Furthermore, no one study has examined 
these four variables as they relate to adherence to treatment recommendations such as 
mental health and substance abuse programs.   
Based on the preceding findings, the current study hypothesized that insight, 
addiction severity, psychiatric symptom severity, and perceived social support would be 
the driving factors in whether or not participants complied with court-mandated mental 
health and substance abuse treatment.  The following hypotheses were proffered: 
1. Level of participant insight will predict non-adherence to court-mandated 
treatment.  Individuals with lower levels of insight will be less likely to recognize 
that they have a SPMI that requires treatment.  Therefore, these individuals will 
be significantly less likely to comply with court-mandated treatment, as evidenced 
by a greater likelihood of experiencing rearrests, re-hospitalizations, positive 
toxicology results, rules violations, and program removals.      
2. Level of addiction severity and insight will yield an interaction that will predict 
non-adherence better than either variable individually.   
3. Level of insight, addiction severity, psychiatric symptom severity, and social 
support combined will best predict non-adherence and this model will account for 
the greatest variability in outcome.  Specifically, individuals with lower levels of 
insight, greater addiction and psychiatric symptom severity, and less social 
support will be significantly less compliant with court-mandated treatment.   
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Chapter 2: Methods 
Participants 
Participants were defendants recruited from the Bronx Mental Health Court 
Program’s Treatment Alternatives for Safer Communities (TASC-MH).  TASC-MH is a 
jail diversion program that offers an alternative to incarceration to defendants with 
mental illness and substance use issues.  Defendants voluntarily agreed to engage in 
and complete treatment for mental illness and substance abuse, while being monitored 
by Bronx TASC-MH.  Individuals ages 18 and older, who were offered and had 
accepted a treatment alternative to incarceration, were invited to participate in the 
current study 
Prior to data collection, an a priori power analysis using G*Power determined that 
a sample size of 55 participants was needed to achieve power at the .80 level for a 
multiple linear regression analysis, using the preceding four predictors.  The final 
sample of the present study contained a total of 73 participants and a post hoc power 
analysis using G*Power determined a power of .90 had been achieved.   
Demographic characteristics of the sample are displayed in Tables 1-3.  The final 
sample (N=73) was comprised of 67.1% (n=49) male and 32.9% (n=24) female 
participants.  Most individuals in the sample identified their ethnicity as Hispanic or 
Latino (52.1%; n= 38), while the remainder of the sample identified as Black (39.7%; n= 
29), White (5.5%; n= 4), Mixed Race (1.4%; n=1), or Asian (1.4%; n= 1).  The mean age 
of participants was 41.88 years (SD = 11.02 years) and the average level of education 
was 10.04 years (SD = 3.05).  A majority of participants identified themselves as single, 
never married (68.5%; n=50), with few participants identifying as currently married 
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(8.2%; n=6) or divorced (21.9%; n=16).  First contact with a mental health professional 
occurred, on average at 20.46 years of age (SD = 11.64).   
Table 1 
 
Gender and Race 
 
Characteristic  Participants (N = 73)  
 N % 
Gender   
   Male 49 67.1 
   Female 24 32.9 
Race   
  Latino/Hispanic  38 52.1 
  Black/African 
American 
29 39.7 
  White 4 5.5 
  Asian 1 1.4 
  Mixed Race 1 1.4 
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Table 2 
 
Age, Education, First Contact with a Mental Health Professional (MHP) 
 
Characteristic  Participants (N = 73)  
 M SD 
Age (years) 41.88 11.02 
Education (years) 10.04 3.05 
First contact with a 
MHP 
20.46 11.64 
Note.  MHP = Mental Health Professional 
 
Table 3 
 
Marital Status 
 
 Participants (N = 73) 
  
 N % 
   
Single, never married 50 68.5 
   
Divorced 16 21.9 
   
Married 6 8.2 
   
   
 
Procedure 
Data collection took place between January 6, 2010 and July 21, 2014.  
Participants were recruited from the Bronx TASC Mental Health Court Program (TASC-
MH). TASC-MH is a voluntary diversion program that offers treatment alternatives to 
incarceration to Bronx County Court defendants who have mental illness and substance 
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use issues.  Defendants who accept TASC-MH agree to receive treatment for mental 
illness and substance use in lieu of being detained in jail or prison.  Individuals who 
accept TASC-MH are monitored by the courts for approximately 18-24 months, until the 
completion of their assigned treatment program.  For the current study, English-
speaking individuals who had accepted diversion through TASC-MH within the past 60 
days were eligible for participation.  Following the completion of intake, individuals who 
met eligibility requirements for the study were identified by the TASC-MH Research 
Coordinator.  Identified individuals were then invited by the Principal Investigator, an 
RA, or a case manager from TASC-MH to participate in a study examining factors that 
affect treatment adherence.  Following the completion of the informed consent 
procedure, individuals who agreed to participate in the study engaged in a 30-40-minute 
clinical interview and completed a series of self-report questionnaires to assess insight, 
psychiatric symptom severity, addiction severity, and perceived social support.   
Clinical interviews were administered by the study’s Principal Investigator or a 
trained Master’s level Research Assistant (RA).  All RAs recruited for the study were 
graduate students with experience in clinical interviewing.  They also received training 
on the study’s assessment measures and further training in clinical interviewing from the 
Principal Investigator and a licensed psychologist, conducted at the site of the study’s 
data collection.  Following multiple training sessions, RAs were observed in two clinical 
interviews and provided with detailed feedback to ensure each RA was following the 
clinical interview protocol.  Additionally, group discussions were conducted for the 
clinician-administered SUMD-R measure in an effort to enhance inter-rater reliability 
among all researchers conducting clinical interviews.  Periodic group check-ins were 
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conducted throughout the data collection period to ensure protocol and scoring 
adherence.  Research assistants also gathered demographic information such as 
gender, age, ethnicity, education, and monthly income from each participant and from a 
file review.  Participants were compensated with a $20 gift card for their time.  
Following each participant’s clinical interview and completion of self-report 
measures, their subsequent three- and six-month follow-up dates were identified.  On 
the scheduled follow-up date, an RA contacted the participant’s assigned case manager 
and solicited information on treatment adherence, using a questionnaire developed for 
this study.  Case managers were asked to provide the number of times since the clinical 
interview (or since the 3-month follow-up) that the participant had been rearrested, 
hospitalized, removed from a program, or tested positive for substances.  They were 
also asked to provide details regarding the cause of each incident and encouraged to 
include any additional information that was relevant to participants’ treatment 
compliance.  Each assigned treatment program had its own set of rules and regulations 
to guide participants’ behavior throughout enrollment in the respective program.  
However, for the purposes of this study, the number and types of rule violations that 
were of interest were those involving the use of unauthorized substances.  With regard 
to program removal, participants were generally asked to leave a program for a number 
of reasons, including repeated positive toxicology results, curfew violations, or physical 
altercations.  In addition to the aforementioned outcome variables, the current study 
also monitored participants’ hospitalizations related to mental illness or substance use.  
All of the above follow-up data were gathered through review of participant files and 
consultation with participants’ assigned case manager.   The number of events in each 
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category was used to determine the participant’s level of treatment adherence to court-
ordered treatment.  Completed questionnaires were collected by an RA within one week 
of the identified follow-up date.  This procedure was followed for both the three- and six-
month follow-up periods. 
Materials 
The following clinical measures were administered to each study participant:  
Insight Scale: (IS; Birchwood, et al., 1994) A self-report measure designed to 
assess patient insight into mental illness.  Participants were asked to agree or disagree 
with statements such as, “I do not need to be seen by a doctor or a psychiatrist” and “I 
do not need medication.”  The IS is scored on a 0-16-point scale.  Higher scores 
indicated a higher level of insight, while lower scores suggested a lack of insight.  This 
scale is often used with individuals with SPMI and has been shown to be an accurate 
measure of insight when used with this population (Birchwood, Smith, Drury, & Healy, 
1994; Drake, et al., 2007; Haq, et. al, 2009; Sitzer, Twamley, Patterson, & Jeste, 2008).   
Scale to Assess Unawareness of Mental Disorder – Revised: (SUMD-R; Amador, 
Strauss, Yale, Gorman, & Endicott, 1991) The SUMD-R is used to asses insight in 
individuals with mental illness.  It has been found to be a strong and accurate measure 
of insight within this population (Amador, et al., 1993; Dias, Brissos, Frey, &Kapczinski, 
2008; Fiss, & Chaves, 2005; Monteiro, Silva, & Louza, 2008).  The SUMD-R is a 
clinician-administered standardized scale designed to assess level of insight into mental 
illness.  The original version of the SUMD-R contains 17 items that require 
administrators to rate participants on a 5-point Likert-type scale on awareness and 
attribution of symptoms such as hallucinations, delusions, and inappropriate affect.  The 
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first three questions on the measure assess participants’ awareness of 1) a mental 
disorder, 2) the effects of medication, and 3) social consequences of having a mental 
disorder.  Previous research studies (Bell et al., 2007; Lysaker, 2006; Marks et al., 
2000; Misdrahi, 2012; Tranulis et al., 2008; Tsang, 2010) examining similar populations 
have used only the first three items of the SUMD-R to assess participants on level of 
insight.  For the purposes of the current study, the methods of the aforementioned 
studies were utilized and only the first three items were used to yield a score on this 
measure.  This was done because many of the current study’s participants did not 
experience the specific symptoms addressed by the instrument, such as hallucinations, 
delusions, thought disorder, and inappropriate affect.  However, the first three items of 
the measure tap into the three widely-researched facets of insight, listed above.  Scale 
administrators were asked to rate participants from 1(aware) to five (completely 
unaware), on current awareness of having a mental illness, the effects of medication, 
and the social consequences of being diagnosed with a mental illness.  The SUMD-R 
was scored on a scale of 0-15.  A higher score was indicative of a more severe lack of 
awareness of one’s mental illness, while a lower scores suggested some awareness of 
mental illness.   
Self-Appraisal of Illness Questionnaire: (SAIQ; Marks, Fasteneau, Lysaker, 
Bond, 2000) A 17-item self-report measure designed to assess patient insight into 
illness.  The questionnaire asked participants to rate their agreement on a Likert-type 
scale on statements and questions such as “Do you believe the current treatment to be 
necessary?” “If I were to discontinue treatment today I would be fine,” I think my 
condition requires psychiatric treatment,” and I have symptoms of mental illness.”  Each 
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question was given a score of 0, 1, 2, or 3 and scores ranged from 0-51.  A higher score 
indicated a more severe lack of insight and an increased belief that symptoms will 
vanish spontaneously, while lower scores indicated some acknowledgement of a need 
for professional treatment. In addition to the SUMD-R, the SAIQ is the second of two 
scales which are used to assess insight in individuals with mental illness.  As it is a self-
report measure, it allows researchers to examine individuals’ self-appraisal of their 
illness. It has been found to be a useful and accurate measure of insight within this 
population (Jovanovski, Zakzanis, Atia, Young, & Campbell, 2007; Marks, Fastenau, 
Lysaker, & Bond, 2000).   
Addiction Severity Index – Self-Report: (McLellan, et al., 1992) A 36-item self-
report measure that assesses the severity and impact of addiction across several 
domains, including employment, health, and family relationships.  The original measure 
asks participants questions regarding the aforementioned domains and the nature of 
their substance abuse within the past month, such as “How many days did you drink 
alcohol in the past 30 days?”  This measure has been used on a number of substance-
abusing populations, and has been used with individuals with mental illness and 
comorbid substance use disorders.  It has been shown to be a valid and reliable tool in 
the assessment of addiction severity (Currie, El-Guebaly, Couson, Hodgins, & Mansley, 
2004; Hodgins, & El-Guebaly, 1992; Zanis, McLellan, & Corse, 1997).  
At the time of their clinical interview, participants in the current study had spent a 
significant portion of the previous 30 days in incarceration.  As it was believed that 
circumstances such as limited access to substances would negatively impact the ability 
to accurately assess participants’ addiction severity, a slight modification was made to 
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this measure’s questions.  To better assess the current study’s population of interest, 
the time period on which participants were asked to report was changed to the 30 days 
prior to the most recent arrest.  For example, participants were asked to fill in blank 
spaces next to questions such as “How many days did you drink alcohol in the 30 days 
prior to your most recent arrest,” “How much money would you say you spent on alcohol 
in the 30 days prior to your most recent arrest,?” and “How many days did you used 
more than one substance (including alcohol) in the 30 days prior to your most recent 
arrest?”   
Colorado Symptom Index: (Ciarolo, Edwards, Kiresuk, Newman, & Brown, 1981) 
A 16-item self-report scale to assess psychiatric symptoms experienced within the past 
six months.  This measure focuses on psychotic symptoms such as hallucinations and 
asked participants to endorse the frequency of symptoms, with questions such as, “In 
the past month, how often have you felt depressed?” and “In the past month, how often 
did you feel suspicious or paranoid?”  Participants were given a score of 1-5 on each 
question and overall scores range from 16-80.  A lower score indicated higher symptom 
severity.  This measure is used frequently with this population and has been found to be 
a reliable and accurate measure of insight (Boothroyd, & Chen, 2008). 
Multidimensional Scale of Perceived Social Support: (Zimet, Dahlem, Zimet, & 
Farley, 1988) A 12-item self-report scale to assess perceived social support from 
significant other, family, and friends.  The scale asked participants to rate their 
agreement (on a Likert-type scale) with statements such as “My family really tries to 
help me,” “I can count on my friends when things go wrong,” and “There is a special 
person in my life who cares about my feelings.”  Each question was given a score 
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between 1 (very strongly disagree) and 7 (very strongly agree) and the total score 
ranged from 12 to 84.  A higher score indicated that the test taker perceived a greater 
level of social support from those around him or her.  This scale has been used with a 
variety of populations and is often used in studies examining perceptions of social 
support among individuals with SPMI (Canty-Mitchell & Zimet, 2000; Chou, 1988; Zimet, 
Powell, Farley, Gordon, & Werkman, 1990). 
Demographic Information, including gender, age, ethnicity, level of education, and 
monthly income, was also collected from both participants and file review. 
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Chapter 3: Results 
 
 
All statistical analyses were completed using version 22.0 of Statistical Package 
for Social Sciences (SPSS, 2013).  The four predictor variables were as follows: 
Psychiatric Symptom Severity (psychsx), Level of Insight (insight), Addiction Severity: 
Alcohol (ASI.alcohol), Addiction Severity: Drugs (ASI.drugs), and Perceived Social 
Support (support). Means and standard deviations for all assessment measures 
administered in the current study are presented in Table 4.  An analysis of the 
correlational relationships between the study’s predictor variables was performed and 
results are presented in Table 5.   
 
 
 
 
 
 
 
 
 
 
 
Table 4 
Means and Standard Deviations of Assessment Measures 
Measure  M  SD 
Symptom Severity   59.15  13.66 
ASI.alcohol  1.72  5.57 
ASI.drugs  0.289  0.167 
Social Support  56.19  14.39 
Insight (BIS)   10.97  3.56 
Insight (SAIQ)  22.45  8.24 
Insight (SUMD-R)  6.41  3.71 
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Table 5 
Correlational Relationships between Predictor Variables 
 
Predictor Sxs Alcohol Drugs Support BIS SAIQ SUMD 
Symptom Severity  1.00       
ASI.alcohol -.016 1.00      
ASI.drugs -0.26* 0.19 1.00     
Perceived Social 
Support 
0.29* 0.14 -.0.04 1.00    
Insight (BIS)  -0.20 0.08 ..18 0.15 1.00   
Insight (SAIQ) 0.52** -0.04 -0.28* 0.05 -0.58 1.00  
Insight (SUMD-R) 0.33** -0.04 -0.17 -0.03 -0.65 0.59 1.00 
Note.  *p < .05.  **p < .01.  Sxs = psychiatric symptoms.   
 
Results yielded significant correlations between several of the predictor 
variables.  As seen in Table 5, a statistically significant correlation was found between 
psychiatric symptom severity and perceived social support (r = 0.29; p = .02), as well as 
insight, as measured by the SAIQ (r = .52; p < .001) and SUMD-R (r = .33; p = .01).  
Additionally, symptom severity yielded a significant negative correlation with drug 
addiction severity (r = -0.26; p = .03).  Drug addiction severity also yielded a significant 
negative correlation with insight, as measured by the SAIQ (r = -0.28; p = .02) such that 
as participants’ drug addiction increased, their level of insight into their SPMI 
decreased.    
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Correlational matrices outlining the magnitude of the relationship between the 
measures used and the outcome variables at 3 and 6 month follow-up can be found in 
Tables 6 and 7.  No significant correlational relationships were found at three months.  
However, at six months several statistically significant relationships were found.  There 
was a significant correlation between alcohol and hospitalization (r = .647, p <.01), 
removal (r = .276, p <.05), and adherence (r = .271, p <.05).  A significant correlation 
was also found between support and removal (r = .305, p <.05). 
Table 6 
 
Correlational Relationships between Three-Month Outcomes and Measures  
 
Three-Month 
Outcome 
Measure 
 Sxs Alcohol Drugs Support BIS SAIQ SUMD 
        
Arrest -.143 -.035 .016 -.072 .065 .013 .032 
Hospitalization .138 -.035 -.178 .056 .001 .152 .019 
Removal -.150 -.068 .005 .031 .002 -.102 -.006 
Toxicology -.141 -.111 .022 -.027 .181 -.156 -.090 
Adherence -.167 -.102 -.008 -.024 .120 -.088 -.031 
        
Note.  *p < .05.  **p < .01.  Sxs = psychiatric symptoms.    
        
Table 7 
 
Correlational Relationships between Six-Month Outcomes and Measures  
 
Six-Month 
Outcome 
Measure 
 Sxs Alcohol Drugs Support BIS SAIQ SUMD 
        
Arrest .163 -.088 -.196 .134 .111 .092 -.043 
Hospitalization .005 .647** -.030 .152 .143 -.024 -.131 
Removal .057 .276* -.077 .305* -.105 .030 .059 
Toxicology -.031 .131 -.077 .017 -.005 .062 -.111 
Adherence .023 .271* -.141 .191 .065 .046 -.090 
        
Note.  *p < .05.  **p < .01.  Sxs = psychiatric symptoms.   
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The frequency of treatment non-compliance for each of the outcome variables 
was measured at three and six months and is presented in Table 8.  The outcome 
variables were substance abuse relapse (as measured by number of substance-related 
rearrests and positive toxicology results), and mental illness relapse (as measured by 
number of re-hospitalizations).   
Table 8 
 
Frequency Distribution of Outcome Variables at Three- and Six-Month Follow-Up 
 
Outcome Participants 
 Three Months n (%) Six Months n (%) 
   
Arrests 8 (11%) 14(19.18%) 
Hospitalizations 1(1.4%) 3(4.11%) 
Program Removals 6(8.2%) 15(20.55%) 
Violations/PositiveResults 12(16.44%) 28(38.36%) 
   
Total 27(36.99%) 60(82.19%) 
 
 
Each of the five outcome variables (i.e., number of rearrests, number of 
hospitalizations related to SPMI or substance abuse relapse, number of rules violations, 
positive toxicology results, number of removals from programs) was measured 
dichotomously, where participants were given a “0” if they had not experienced the 
event in question or a “1” if they had.  For example, if a participant had experienced one 
or more re-arrests during the three-month follow-up period, (s)he would receive a “1” in 
that category.  If (s)he did not experience any re-arrests during the three-month follow-
up, (s)he would receive a “0.”  Up on further investigation of participants’ follow-up data, 
it was determined that each individual who had experienced a rule violation had done so 
due to positive toxicology results.  Therefore, the “positive toxicology results” and “rules 
violations” variables were collapsed into a single category, leaving four outcome 
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variables.  To determine the rate of overall compliance for each participant, a composite 
variable, labeled “adherence,” was created.  To calculate the program adherence 
variable, the sum of the converted dichotomous scores on the individual outcome 
variables was calculated for each participant. For example, a participant who had 
experienced one or more re-arrests, re-hospitalizations, or rules violations would 
receive an adherence score of “3,” while a participant who did not experience any re-
arrests, re-hospitalizations, rules violations, positive toxicology results, or removals from 
programs would receive a “0.”  This procedure was followed for both the three- and six-
month follow-up periods and each participant was given a three-month adherence and 
six-month adherence score.     
Regression Analysis 
Linear and logistic regression analyses were used to examine the relationships 
between predictor and outcome variables, as they related to the study’s original 
hypotheses.   
First, level of insight was hypothesized to be a significant predictor of participant 
adherence. To examine differences in level of insight between those individuals who 
experienced rearrests, re-hospitalizations, rules violations, positive toxicology results, 
and program removals and those individuals who did not, independent samples t-tests 
were performed.  Each measure of insight was used as a continuous predictor in a 
separate model.  As insight was measured continuously, the grand mean score of each 
measure was used as a cutoff to separate participants into two groups (i.e., high insight 
and low insight).  The cutoff score for each insight measure can be found in Table 4.  
Contrary to expectation, individuals with low levels of insight (M = 0.14, SD = 0.35) 
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experienced significantly fewer positive toxicology results at three months than 
individuals with high levels of insight (M = 0.18, SD = 0.39), t(71) = -2.46, p = .016.  The 
assumption of homogeneity of variances was met, as assessed by Levene’s test for 
equality of variance (p = n.s.).  No additional significant differences were found between 
individuals with high and low insight, in relation to overall adherence.    
Logistic regression analysis was performed for three- and six-month follow-up 
periods, using level of insight as the predictor variable and each of the following as 
outcome variables: rearrests, re-hospitalizations, rules violations/positive toxicology 
results, and program removals (Tables 9, 10, & 11).   
 
 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p OR Lower Upper 
         
Three Months        
        
Arrest  .154 .157 .959 1 .328 1.166 .857 1.586 
Hosp .899 .930 .936 1 .333 2.458 .398 15.200 
Removal -.056 .163 .118 1 .731 .945 .687 1.301 
Tox. .174 .144 1.464 1 .226 1.190 .898 1.578 
         
Six Months         
        
Arrest  .298 .216 1.901 1 .168 1.347 .882 2.056 
Hosp .816 .681 1.436 1 .231 2.261 .595 8.587 
Removal -.102 .135 .563 1 .453 .903 .693 1.178 
Tox. -.057 .117 .236 1 .627 .945 .752 1.188 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Tox. = rules violations/positive 
toxicology results. 
Table 9 
 
Logistic Regression Analysis: Predicting Outcome at Three and Six Months with the BIS 
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Table 10 
 
Logistic Regression Analysis: Predicting Outcome at Three and Six Months with the SAIQ 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
Three Months         
        
Arrest  .018 .062 .087 1 .768 1.019 .902 1.151 
Hosp .766 .628 1.484 1 .223 2.150 .628 7.367 
Removal -.071 .066 1.173 1 .279 .931 .819 1.059 
Tox. -.036 .050 .512 1 .474 .965 .874 1.065 
         
Six Months        
        
Arrest  .127 .082 2.377 1 .123 1.135 .966 1.333 
Hosp .117 .154 .583 1 .445 1.125 .832 1.520 
Removal -.015 .056 .073 1 .787 .985 .883 1.099 
Tox. .051 .047 1.171 1 .279 1.052 .960 1.153 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Tox. = rules violations/positive toxicology 
results. 
         
Table 11 
 
Logistic Regression Analysis: Predicting Outcome at Three and Six Months with the SUMD 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
         
Three Months        
         
Arrest  .098 .138 .506 1 .477 1.103 .841 1.447 
Hosp .001 .661 .000 1 .998 1.001 .274 3.656 
Removal .056 .161 .120 1 .729 1.058 .771 1.450 
Tox. .048 .124 .148 1 .700 1.049 .822 1.338 
         
Six Months        
         
Arrest  -.026 .174 .022 1 .882 .974 .693 1.371 
Hosp -.742 .750 .978 1 .323 .476 .110 2.071 
Removal .001 .136 .000 1 .992 1.001 .767 1.307 
Tox. -.180 .122 2.189 1 .139 .835 .658 1.060 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Tox. = rules violations/pos. tox. results. 
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As seen in the preceding tables, no significant results were found and insight was 
not shown to be a significant predictor of outcome at three or six months for any of the 
aforementioned outcome variables.   
Simple linear regression was then performed using insight as the predictor and 
the three- and six-month composite adherence variables as outcomes.  Results can be 
found in Table 12.  No significant relationships were found between insight and any of 
the aforementioned outcome variables, suggesting insight was not a predictor of 
adherence in the current study.   
Table 12      
      
Linear Regression Analysis: Insight as a Predictor of Outcome at Three and Six Months 
      
    95% CI for B 
 B t p Lower Upper 
      
Three Months     
      
BIS .032 .933 .354 -.036 .100 
SAIQ -.005 -.394 .695 -.033 .022 
SUMD .021 .632 .530 -.045 .087 
      
Six Months      
      
BIS .016 .412 .682 -.061 .093 
SAIQ .017 1.104 .274 -.014 .049 
SUMD -.033 -.873 .386 -.108 .042 
      
Note.  *p < .05.  **p < .01.   
 
Next, it was hypothesized that there would be a moderating effect between level 
of insight and addiction severity.  To test this hypothesis, the relationship between 
addiction severity and adherence was examined.  Logistic regression analysis was 
again performed using alcohol addiction severity and drug addiction severity as 
predictors and each of the study’s dichotomous outcomes (i.e., rearrests, re-
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hospitalizations, rules violations/positive toxicology results, and program removals) as 
dependent variables.  Results of the logistic regression can be found in Tables 13 and 
14. 
Table 13 
 
Logistic Regression Analysis: Addiction Severity as a Predictor of Outcome at Three Months 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
Alcohol        
         
Arrest  -.38 .124 .094 1 .759 .963 .756 1.227 
Hosp -3.765 950.831 .000 1 .997 .023 .000 - 
Removal -.434 .494 .771 1 .380 .648 .246 1.706 
Tox. -.752 .521 2.081 1 .149 .471 .170 1.310 
         
Drugs        
         
Arrest  .489 2.285 .046 1 .830 1.631 .019 143.719 
Hosp -595.16 30046.086 .000 1 .984 .000 .000 - 
Removal 1.217 2.724 .200 1 .655 3.377 .016 703.591 
Tox. 2.003 2.090 .918 1 .338 7.408 .123 445.084 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Tox. = rules violations/positive toxicology 
results. 
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Table 14 
 
Logistic Regression Analysis: Addiction Severity as a Predictor of Outcome at Six Months 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
Alcohol        
         
Arrest  -3.418 3.792 .813 1 .367 .033 .000 55.347 
Hosp .228 .162 1.973 1 .160 1.256 .914 1.726 
Removal .107 .077 1.938 1 .164 1.113 .957 1.293 
Tox. .052 .048 1.168 1 .280 1.053 .959 1.157 
         
Drugs        
         
Arrest  -3.274 3.311 .813 1 .323 .038 .000 24.905 
Hosp -10.426 10.365 1.012 1 .314 .000 .000 19709.992 
Removal -2.555 2.484 1.058 1 .304 .078 .001 10.115 
Tox. -1.543 1.832 .709 1 .400 .214 .006 7.754 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Tox. = rules violations/positive toxicology 
results. 
 
Linear Regression was used to examine whether addiction severity was a 
significant predictor of adherence at three and six months.  The results of this analysis 
can be found in Table 15.  The variables ASI.alcohol and ASI.drugs were entered as 
predictors and three-month and six-month adherence were each entered as the 
dependent variable in separate models.  The final regression model at three months 
was a poor fit (R2 adj. = -.018), with no single variable contributing significantly to the 
model.  The final regression model at six months was significant (R2 adj. = .086), with 
ASI.alcohol being a significant predictor within the model (p = .02).  No additional 
significant relationships were found.   
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Table 15      
      
Linear Regression Analysis: Addiction Severity as a Predictor of Adherence at Three and Six 
Months 
      
    95% CI for B 
 B t p Lower Upper 
      
Three Months     
      
Alcohol  -.014 -.863 .391 -.046 .018 
Drugs .050 .094 .925 -1.013 1.114 
      
      
Six Months      
      
Alcohol  .046 2.690 .009** .012 .080 
Drugs -.996 -1.739 .087 -2.138 .147 
      
      
Note.  *p < .05.  **p < .01.   
 
In order to assess moderation, a moderation term labeled “insight x alcohol x 
drugs” was created. Linear regression was then used to determine the ability of the 
aforementioned variables to predict adherence at three and six months.  Predictors 
were entered into the analysis in blocks, with insight, alcohol addiction severity, and 
drug addiction severity comprising the first block and the insight x alcohol x drugs 
interaction variable in the second block.  As seen in Table 16, the model yielded 
significant results (F [3, 69] = 2.90, p = .04) and accounted for approximately 7.3% of 
the total variance in adherence to court-mandated treatment.  Within the Model, alcohol 
addiction severity was the sole significant predictor of adherence (p = .01).  Although 
ASI.alcohol was shown to be a predictor of adherence, results of the data analyses did 
not support this hypothesis, as there was no evidence of an interaction between insight 
and addiction severity. 
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Table 16    
       
Linear Regression Analysis: Insight and Addiction Severity as a Predictor of Adherence at 
Three and Six Months 
       
     95% CI for Odds Ratio 
 Adj. R2 B  t p Lower Upper 
Three Months      
Block 1 -.024      
SAIQ  -.009 -.773 .442 -.031 .014 
Alcohol  -.014 -.851 .398 -.046 .018 
Drugs   -.069 -.124 .902 -1.179 1.041 
       
Block 2 -.006      
Interaction  -.016 -.740 .462 -.058 .027 
       
Six Months        
       
Block 1 .073      
SAIQ  .005 .386 .701 -.019 .029 
Alcohol  .017 2.670 .009** .012 .081 
Drugs   -.992 -1.652 .103 -2.190 .206 
       
Block 2 -.012      
Interaction  .001 .023 .982 -.047 .049 
       
Note.  *p < .05.  **p < .01.  Interaction = insight x alcohol x drugs. 
 
Finally, it was predicted that level of insight, addiction severity, psychiatric 
symptom severity, and social support combined would predict non-adherence better 
than any of the four variables alone.  Linear Regression (Table 17) was used to 
examine this hypothesis.  The preceding variables were entered as predictors and 
three-month and six-month adherence were each entered as the dependent variable in 
separate models.  The final regression model at three months was a poor fit (R2 adj. = -
.029), with no single variable contributing significantly to the model.  Similarly, the final 
regression model at six months was also a poor fit (R2 adj. = .057), with ASI.alcohol 
being a significant predictor within the model (p = .02).  The remaining variables, insight, 
psychsx, ASI.drugs, and support, did not contribute significantly to the model. 
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Table 17    
       
Linear Regression Analysis: Combined Outcome Variables as Predictors of Adherence at 
Three and Six Months 
       
     95% CI for Odds Ratio 
 Adj. R2 B t p Lower Upper 
Three Months      
 -.029      
Insight  .005 .346 .730 -.026 .037 
Alcohol  -.019 -1.168 .247 -.053 .014 
Drugs  -.175 -.312 .756 -1.298 .947 
Sxs   -.013 -1.604 .114 -.030 .003 
Support   .002 .275 .784 -.011 .015 
       
Six Months        
 .057      
Insight  .011 .628 .532 -.024 .045 
Alcohol  .042 2.234 .023* .006 .078 
Drugs  -.969 -1.588 .117 -2.187 .250 
Sxs   -.002 -.188 .852 -.020 .016 
Support   .008 1.117 .268 -.006 .023 
       
Note.  *p < .05.  **p < .01.  Sxs = Psychiatric Symptoms. 
 
Using the “enter” method, a Logistic Regression analysis was conducted to 
determine whether  psychiatric symptom severity, level of insight, addiction severity, 
and social support were significant predictors of arrests, hospitalizations, program 
removals, and rules violations/positive toxicology results at three and six months.   
Results (shown in Tables 18 and 19) show that support predicted program removal at 
six months.  None of the remaining independent variables were significant predictors of 
outcome at three or six months.   
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Table 18 
 
Logistic Regression Analysis: Predictors of Outcome at Three Months 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
         
Arrests         
  Alcohol -.058 .142 .164 1 .686 .944 .714 1.248 
  Drugs .179 2.525 .005 1 .943 1.197 .008 168.724 
  Sxs  -.054 .035 2.415 1 .120 .948 .886 1.014 
  Supp.  -.009 .031 .089 1 .766 .991 .933 1.053 
  BIS .212 .165 1.667 1 .197 1.237 .896 1.707 
  SAIQ .077 .075 1.058 1 .304 1.080 .933 1.250 
  SUMD .129 .140 .854 1 .355 1.138 .865 1.496 
         
Hosp.         
  Alcohol -1.645 4039.890 .000 1 1.000 .193 .000 - 
  Drugs -147.57 69300.682 .000 1 .998 .000 .000 - 
  Sxs  1.002 473.864 .000 1 .998 2.723 .000 - 
  Supp.  .573 259.679 .000 1 .998 1.773 .000 - 
  BIS 6.420 1607.981 .000 1 .997 614.099 .000 - 
  SAIQ 3.657 433.192 .000 1 .993 38.755 .000 - 
  SUMD .917 639.959 .000 1 .999 2.501 .000 - 
         
Removal         
  Alcohol -.760 .589 1.664 1 .197 .468 .147 1.484 
  Drugs 1.588 3.253 .238 1 .625 4.864 .008 2875.626 
  Sxs  -.067 .043 2.415 1 .120 .935 .859 1.018 
  Supp. .050 .038 1.728 1 .189 1.052 .976 1.134 
  BIS -.088 .172 .262 1 .608 .916 .654 1.282 
  SAIQ -.067 .087 .590 1 .443 .936 .789 1.109 
  SUMD .158 .179 .787 1 .375 1.172 .826 1.663 
         
Tox.         
  Alcohol -.914 .593 2.373 1 .123 .401 .125 1.283 
  Drugs 1.485 2.267 .429 1 .513 4.414 .052 375.626 
  Sxs  -.044 .032 1.950 1 .163 .957 .899 1.018 
  Supp. .013 .027 .232 1 .630 1.013 .961 1.067 
  BIS .190 .155 1.493 1 .222 1.209 .892 1.640 
  SAIQ -.004 .062 .033 1 .955 .996 .883 1.125 
  SUMD .074 .132 .314 1 .575 1.077 .831 1.394 
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Supp. = Support.  Sxs = Psychiatric 
Symptoms.  Tox. = rules violations/positive toxicology results. 
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Table 19 
 
Logistic Regression Analysis: Predictors of Outcome at Six Months 
         
       95% CI for Odds 
Ratio 
 B SE Wald df p Odds 
Ratio 
Lower Upper 
         
Arrests         
  Alcohol -4.193 4.461 .883 1 .347 .015 .000 94.737 
  Drugs -2.836 3.210 .781 1 .377 .059 .000 31.665 
  Sxs  .026 .056 .215 1 .643 1.026 .919 1.146 
  Supp. .021 .037 .326 1 .568 1.021 .950 1.098 
  BIS .426 .309 1.902 1 .168 1.531 .836 2.806 
  SAIQ .131 .101 1.688 1 .194 1.140 .935 1.390 
  SUMD .027 .185 .021 1 .884 1.027 .714 1.478 
         
Hosp.         
  Alcohol 6.916 162.233 .002 1 .966 1008.743 .000 1.251 
  Drugs -384.80 11835.1 .001 1 .974 .000 .000 - 
  Sxs  2.930 185.851 .000 1 .987 18.735 .000 2.948 
  Supp. -.150 43.367 .000 1 .997 .861 .000 7.063 
  BIS 95.858 2045.968 .000 1 .963 4.270 .000 - 
  SAIQ 28.295 616.325 .002 1 .963 1.943 .000 - 
  SUMD -116.83 2409.89 .002 1 .961 .000 .000 - 
         
Removal         
  Alcohol .094 .068 1.876 1 .171 1.098 .960 1.256 
  Drugs -1.892 2.858 .438 1 .508 .151 .001 40.869 
  Sxs  .004 .044 .010 1 .921 1.004 .921 1.095 
  Supp. .081 .037 4.805 1 .028* 1.085 1.009 1.167 
  BIS -.203 .154 1.736 1 .188 .816 .603 1.104 
  SAIQ -.065 .078 .691 1 .406 .937 .804 1.092 
  SUMD -.011 .158 .005 1 .946 .989 .727 1.347 
         
Tox.         
  Alcohol .048 .051 .889 1 .346 1.050   
  Drugs -1.476 1.944 .577 1 .448 .229   
  Sxs  -.012 .027 .199 1 .655 .988   
  Supp. .003 .024 .019 1 .891 1.003   
  BIS -.061 .123 .241 1 .623 .941   
  SAIQ .054 .055 .969 1 .325 1.055   
  SUMD -.180 .124 2.119 1 .145 .835   
         
Note.  *p < .05.  **p < .01.  Hosp. = hospitalization.  Supp. = Support.  Sxs = Psychiatric 
Symptoms.  Tox. = rules violations/positive toxicology results. 
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Chapter 4: Discussion 
For individuals with SPMI, getting treatment in addition to medication is very 
important and treatment adherence can prevent decompensation, frequent 
hospitalizations, frequent contact with the criminal justice system, and disruptions in 
their lives, and the lives of their family and friends.  The current study aimed to examine 
the client-centered factors that most heavily impact psychological and substance abuse 
treatment adherence among this population.  Overall we found that insight was found to 
be significantly correlated with psychiatric symptom severity and drug addiction severity, 
however contrary to expectation we did not find that insight was a significant predictor of 
treatment compliance.  Further, we also did not find that a combination of factors 
commonly related to medication non-compliance among those with SPMI (i.e., insight, 
addiction severity, psychiatric symptom severity, and social support) predicted 
adherence to psychological and substance abuse treatment better than each of the 
variables individually.  However, we did find that addiction severity (as measured by the 
ASI) and social support were significant predictors at six months. While much of the 
previous literature on compliance found a correlation between medication compliance 
and insight (Brain, et al., 2013; Segarra, et al., 2012), we failed to replicate those 
findings in the current study.    This could be for a number of reasons.  First, the majority 
of the studies that found insight to be a predictor of compliance largely examined 
medication compliance and not compliance with other aspects of treatment.  This study 
looked at adherence to other aspects of treatment, such as substance abuse and 
mental health treatment programs and there may be different issues related to 
medication compliance and treatment compliance.  Second, many studies measured 
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compliance via participant self-report and did not include objective indicators, such as 
blood analysis.  To assess compliance in the current study, objective indicators, such as 
positive toxicology results, rearrests, and hospitalizations were recorded; this may have 
resulted in a more accurate assessment of compliance.  Finally, many other studies 
(Brain, et al., 2013; Segarra, et al., 2012) excluded individuals who met the criteria for 
Substance Use Disorder.  The current study specifically aimed to investigate treatment 
compliance among individuals with both a SPMI and substance use concerns, as 
research suggests a significant portion of individuals with SPMI are estimated to have 
co-occurring substance use disorders.  These co-occurring disorders have been 
empirically shown to negatively affect treatment compliance and impact the relationship 
between variables such as insight and adherence to recommended treatment (Buckley, 
et al., 2009; Tsai & Rosenheck, 2013).   
 The main findings of this study were that addiction severity and social support 
predicted treatment compliance with psychological and substance abuse programming 
better than either of the other client-centered variables assessed.  The previous findings 
on the relationship between treatment compliance and addiction severity were mixed 
with some studies reporting a relationship (Cesares-Lopez, et al., 2011; Doyle & 
Donovan, 2014; Killeen, Brady, & Thevos, 1995), and others not (Sterling, Gottheil, 
Glassman, Weinstein, & Serota, 1997; Tkacz, Severt, Cacciola, & Reutsch, 2012).  
There was also a significant negative correlation found between drug addiction severity 
and insight, suggesting that, as participants’ drug addiction severity increased, their 
level of insight decreased.  This finding is closely aligned with research that suggests 
individuals with severe drug use and/or addiction have lower levels of insight and are 
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oftentimes less likely to comply with treatment recommendations (Cacciola, Dugosh, & 
Camilleri, 2009).   This may indicate that, for individuals with SPMI and addiction, as the 
severity of their addiction increases, their ability to recognize the need for treatment and 
intervention is significantly impacted.  It also seems that these individuals may have a 
difficult time abstaining from substances once they do attempt to enter a treatment 
program.   
A second finding of the current study was that social support predicted program 
removal at six months.  This finding was somewhat unexpected, as it was hypothesized 
that higher levels of perceived social support would result in participants being better 
equipped to remain in an assigned program and better navigate their way through the 
sometimes demanding expectations of the treatment process.  As there were numerous 
reasons why a participant might have been removed from a treatment program in the 
current study (including multiple rules violations which may have been related to 
continued substance use), it is unclear why participants in our sample were more likely 
to be removed from a program if they had higher levels of perceived support.   However, 
this finding is in line with research by Comfort, et al. (2003) who found that type of 
support may have a differential impact on overall treatment outcome.  Specifically, the 
authors found that support from non-substance-users was a significant contributor to 
improved treatment outcome.  Conversely, those individuals in the study who received 
support from substance users experienced less favorable treatment outcomes, as they 
were less likely to maintain abstinence.  The findings related to social support in the 
current study are also in line with research suggesting that alcohol-specific support (i.e., 
social support for abstinence and support for continued use) significantly impacts 
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whether an individual will continue drinking after enrolling in or being discharge from 
treatment (Hunter-Reel, McCrady, Hildebrandt, & Epstein, 2010; Longabaugh, Wirtz, 
Zywiak, & O’Malley, 2010; Nargiso, Kuo, Zlotnick, & Johnson, 2014).  Considered 
together, this information suggests that, in the current study individuals with higher 
levels of support who were subsequently removed from treatment programs may have 
had support from individuals who continued to use substances. Further examination of 
the differential impacts of differing social support sources on treatment compliance is 
warranted.   
Contrary to expectation, we did not find that the combination of patient centered 
variables which included insight, psychiatric symptom severity, addiction severity, and 
social support predicted treatment compliance among individuals with SPMI and 
substance use issues who had been court-mandate to receive treatment for both.  
Despite addiction severity being shown to be a significant predictor of adherence, the 
other three variables showed no such significant relationship.  As determined by 
previous studies, while insight, psychiatric symptom severity, and support may have a 
connection with an individual’s likelihood of complying with treatment recommendations, 
they may not be the strongest predictors of it.  It seems there may have been other 
variables not measured by the current study that may be stronger predictors of 
expected treatment compliance.  With regard to insight, considering the large body of 
literature that supports it as a significant predictor of compliance, it is possible that the 
current study’s failure to replicate those results may stem from its measurement of 
insight. In the current study insight was rated by individuals who were not familiar with 
the participants following a brief, 30-45-minute clinical interview.  Although the current 
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study utilizes well-known and widely-used insight measures, previous research 
generally used raters with a higher level of familiarity with participants whose level of 
insight was assessed.  Some studies even assessed insight over repeated interactions 
with participants.  This may have left researchers better equipped to rate actual level of 
insight, as oppose to merely assessing whether an individual has accepted the label of 
mental illness.  This may lead to an inaccurate assessment, as some individuals may 
simply state they have a SPMI without appreciating the other aspects of the concept 
(e.g., the benefits of medication and social consequences of having a mental illness).    
In addition to the preceding findings, the current study yielded several significant 
correlational relationships between predictor variables.  First, there were significant 
correlations between psychiatric symptom severity and insight, drug addiction severity 
(in the negative direction), and support.  This suggests that those participants with 
greater symptom severity also had greater addiction severity, lower levels of insight into 
their SPMI, and less social support.  This finding highlights the complicated relationship 
between the aforementioned variables and is supported by previous research studies 
that found psychiatric symptom severity to be closely related to insight and addiction 
severity, as they relate to treatment adherence (Buckley, et al., 2009; Saeedi, 
Addington, & Addington, 2007; Tsai & Rosenheck, 2013).  Psychiatric symptom severity 
may play a key role in adherence because it is so closely related to addiction severity, 
insight, and social support, as suggested by the current study’s significant correlation 
between these four variables.  As suggested by this and previous research, these 
variables appear to be closely related and influential in whether an individual will comply 
46 
 
with treatment.  However, they may not be the most impactful when it comes to 
predicting treatment compliance.   
A growing body of research suggests patient-centered variables other than those 
examined in the current study also impact treatment adherence among individuals with 
mental illness and substance use disorders.  For example, some studies have found 
that self-stigma and views toward having a mental illness decreased participants’ level 
of treatment adherence (Fung, et al., 2010; Fung, Tsang, & Corrigan, 2008; Sirey, et al., 
2001).  Other studies have found that treatment readiness, as measured by the Stages 
of Change, plays a significant role in whether patients adhere to treatment regiments 
(Tsang, Fung, & Chung, 2010).  Additionally, attitudes toward medication have also 
been found to contribute to treatment non-adherence among patients with negative 
views of medication (Sajatovic, et al., 2008) and better adherence and functioning for 
patients with more positive medication attitudes (Mohamed, et al., 2009).  The 
preceding information contributes to the existing complexity of treatment compliance 
and researchers’ understanding of it.   Perhaps these variables, in addition to addiction 
severity and social support may be better indicators of treatment compliance adherence 
among individuals with mental illness and substance use disorders. 
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Limitations 
 The current study had several limitations which may have impacted its results.  
First, the follow-up periods of three and six months may not have been long enough to 
detect useful data on events such as treatment completion, rearrests, and re-
hospitalizations.  TASC-MH is a jail-diversion program that takes participants between 
18 and 24 months to complete, which means the current study’s follow-up period only 
lasted through the first quarter to one-third of TASC-MH’s mandated treatment program.  
It is possible that, with the passing of more time, more participants in the current study 
may have experienced a SPMI-related relapse.  Second, only those defendants who 
accepted TASC-MH were sampled.  It is possible that those clients were more 
motivated than other individuals to succeed and less likely to be non-adherent to 
mandated treatment or experience relapses, re-hospitalizations, and program removals. 
A third limitation is the study’s assessment of insight.  As previously discussed, the 
relationship between insight and treatment compliance has been extensively supported 
by a large body of research.  Although significant correlational relationships were found, 
the current study’s failure to find a significant predictive relationship between insight and 
the outcome variables may point to a limitation in the way the current study measured 
insight.  While the clinician-administered measure of insight is widely used and 
accepted and has been empirically validated, the way in which it was utilized in the 
current study may not have been ideal.  Specifically, the clinicians administering the 
measure did not have any prior knowledge of or experience with each participant for 
which they were asked to rate level of insight.  It is possible that participants’ individual 
case manager may have had more extensive knowledge of the participant’s level of 
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insight, based on multiple meetings and conversations with the participant.  The final 
limitation is the study’s modification of the ASI Self-Report to better accommodate the 
large proportion of participants who had been incarcerated at some point during the 30 
days prior to the clinical interview.  The psychometric properties of the modified ASI 
have not been empirically examined and it is, therefore, unknown whether the current 
study’s modified version of the ASI was valid or reliable.   
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Directions for Future Research 
Future research should further examine the roles of addiction severity and social 
support in treatment compliance, with the ultimate goal of determining whether these 
variables might benefit from being a focus of treatment interventions.  The finding of 
addiction severity as a significant predictor of adherence is an important one, as it may 
indicate that participants with a more severe addiction may be more likely to continue 
using substances once they have entered a treatment program.  Due to this possibility, 
accurate assessment of addiction severity at program intake may be crucial, as it may 
help determine the best course of action for treatment providers.  If the severity of one’s 
substance addiction affects the likelihood of subsequent adherence, individuals with 
higher levels of addiction may require different or more intensive intervention at the 
outset of and/or during treatment.  If this is the case, it may be possible to identify these 
individuals during intake or early in a given treatment program in order to provide them 
with increased guidance or additional relapse prevention strategies.  It may also be 
important to examine whether the substance an individual uses may impact addiction 
severity and the ways in which this interaction might affect compliance.  This would help 
researchers to develop an even clearer picture of the impact of addiction severity and 
lead to improved interventions for longer lasting treatment compliance.  
The current study also found social support to be a predictor of compliance.  If 
the type and source of social support one is receiving will have a significant impact on 
whether an individual remains in a particular program, it may help to assess individuals’ 
sources of support at the beginning of treatment.  While some individuals may have a 
variety of support sources, both positive and negative, others may lack support from 
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positive, non-substance-using sources.  Those individuals may be in need of additional 
intervention in the form of help creating positive social networks and connection to 
people who support abstinence and recovery.  This may increase the likelihood of 
remaining in a given treatment program and maintaining long-term success.   
Despite the current study’s findings, a large body of research suggests that 
insight actually is a significant factor in whether an individual will comply recommended 
treatment.  Accordingly, future research may benefit from continued investigation of the 
impact of this variable on compliance. This information can also be connected to 
research on changes in insight over the course of treatment, as well as the 
effectiveness of insight therapy among this population.   
Finally, as stated previously, a growing body of research suggests variables such 
as self-stigma, views toward mental illness, treatment readiness, and attitudes toward 
medication also impact treatment compliance.   Therefore, researchers may wish to 
include an examination of these factors in addition to those found to be significant by 
the current study, as they may help to develop a clearer picture of the most important 
factors that affect treatment compliance among individuals with mental illness and a 
substance use disorder.   
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*Developed by Xavier F. Amador, Ph.D., and David H. Strauss, M.D.,  Schizophrenia Research Unit, New York State Psychiatric 
Institute, Unit #2, 722 West 168th  St., NY, NY 10032.  Duplication prohibited without permission.  Version 3.1 REVISED: 
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